Try our Advanced Search for more refined results

KING DRUG COMPANY OF FLORENCE, INC vs. CEPHALON, INC., ET AL

  1. December 15, 2015

    Provigil Buyers' Per Se Theory Nixed In Pay-For-Delay Row

    A Pennsylvania federal judge on Monday said the generic-drug manufacturers accused of accepting $300 million from Cephalon Inc. to delay generic versions of narcolepsy drug Provigil won't face a per se theory of liability at trial for allegedly knowing the patent was unenforceable, as they had no involvement in its procurement.

  2. November 20, 2015

    Mylan, Ranbaxy Urge Stay Of Provigil Pay-For-Delay Suits

    Mylan Inc. and Ranbaxy Laboratories Ltd. on Thursday urged a Pennsylvania federal judge to stay three cases accusing them and others of accepting $300 million from Cephalon Inc. to delay generic versions of its narcolepsy drug Provigil, pending their effort to overturn a class certification order in the Third Circuit.

  3. November 06, 2015

    Provigil Judge Says Experts Can Testify On Patent Strength

    A Philadelphia federal judge ruled Thursday that drugmakers could use evidence at an upcoming pay-for-delay antitrust trial over Provigil about the strength of the narcolepsy drug patent if purchasers argue that the settlement was a bid to shield a weak patent.

  4. October 15, 2015

    Teva's $512M Provigil Deal Looks Good To Judge

    A Pennsylvania federal judge said Thursday that he would approve a $512 million settlement between direct purchasers and Teva Pharmaceutical Industries Ltd. plus subsidiaries Cephalon Inc. and Barr Pharmaceuticals Inc. in pay-for-delay litigation over Cephalon's narcolepsy drug Provigil.

  5. September 18, 2015

    Provigil Buyers Want $141M In Fees For Cephalon Deal

    Direct buyers of Provigil pressed a Pennsylvania federal court Thursday to award them about $141 million in legal fees for their work in securing a $512 million settlement with Teva Pharmaceutical Industries Ltd. and subsidiaries Cephalon Inc. and Barr Pharmaceuticals Inc. in pay-for-delay litigation.

  6. September 15, 2015

    Provigil Buyers Again Say Class Cert. Order Needs Tweaking

    Direct buyers of Provigil pressed a Pennsylvania federal court again Tuesday to modify a class certification order in the pay-for-delay litigation, saying the opposition by generic-drug makers Mylan Pharmaceuticals Inc. and Ranbaxy Pharmaceuticals Inc. runs contrary to basic antitrust principles.

  7. September 11, 2015

    Mylan, Ranbaxy Slam Bid To Change Provigil Class Cert.

    Generic-drug makers Mylan Pharmaceuticals Inc. and Ranbaxy Pharmaceuticals Inc. have urged a Pennsylvania federal judge to reject a request by direct buyers of Provigil to modify a class certification order in the pay-for-delay litigation, saying it clearly lays out the claims and issues that will be tried.

  8. August 25, 2015

    Provigil Buyers Say Drug Cos. Twisting Class Cert. Order

    Direct Provigil buyers told a Pennsylvania federal judge Monday they were worried Mylan Pharmaceuticals Inc. and Ranbaxy Pharmaceuticals Inc. would try to manipulate a class certification order to improperly limit the issues in the pay-for-delay litigation, asking the court to tweak the ruling.

  9. August 13, 2015

    Pa. Judge Narrows Class In Provigil Pay-For-Delay Suit

    A Pennsylvania federal judge on Thursday narrowed the defined class of direct purchasers of Cephalon Inc.'s narcolepsy drug Provigil in a suit accusing Mylan Pharmaceuticals Inc. and Ranbaxy Pharmaceuticals Inc. of making illegal pay-for-delay deals.

  10. July 27, 2015

    Provigil Buyers Win Class Cert. In Pay-For-Delay Fight

    A Pennsylvania federal judge on Monday certified a class of direct purchasers of Cephalon Inc.'s narcolepsy drug Provigil, despite strong objections from the two generic-drug makers accused of inking illegal pay-for-delay deals.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!